参考文献
1: Kawamura I, Lacey E, Yamamoto N, Sakai F, Takeshita S, Inami M, Nishigaki F, Naoe Y, Tsujimoto S, Manda T, Shimomura K, Goto T. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice. Anticancer Res. 1999 Sep-Oct;19(5B):4105-11. PubMed PMID: 10628361.
2: Kawamura I, Lacey E, Inami M, Nishigaki F, Naoe Y, Tsujimoto S, Manda T, Goto T. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI. Anticancer Res. 1999 Sep-Oct;19(5B):4091-7. PubMed PMID: 10628359.
3: Kawamura I, Yamamoto N, Sakai F, Yamazaki H, Naoe Y, Inami M, Manda T, Shimomura K. Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor. Anticancer Res. 1999 Jan-Feb;19(1A):341-8. PubMed PMID: 10226565.
4: Laudadio C, Sima AA. Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial. Ponalrestat Study Group. J Diabetes Complications. 1998 May-Jun;12(3):121-7. PubMed PMID: 9618066.
5: Otter DJ, Chess-Williams R. The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats. Br J Pharmacol. 1994 Oct;113(2):576-80. PubMed PMID: 7834210; PubMed Central PMCID: PMC1510137.
6: Taylor PD, Wickenden AD, Mirrlees DJ, Poston L. Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin-induced diabetes: effect of treatment with the aldose reductase inhibitor, ponalrestat. Br J Pharmacol. 1994 Jan;111(1):42-8. PubMed PMID: 8012723; PubMed Central PMCID: PMC1910054.
7: Reddi AS, Jyothirmayi GN. Aldose reductase inhibition by ponalrestat (statil) does not prevent proteinuria in long-term diabetic rats. J Diabetes Complications. 1993 Oct-Dec;7(4):233-40. PubMed PMID: 8219366.
8: Boland OM, Blackwell CC, Clarke BF, Ewing DJ. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus. Diabetes. 1993 Feb;42(2):336-40. PubMed PMID: 8425670.
9: Cameron NE, Cotter MA. Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats. Br J Pharmacol. 1992 Dec;107(4):939-44. PubMed PMID: 1467842; PubMed Central PMCID: PMC1907934.
10: Krentz AJ, Honigsberger L, Ellis SH, Hardman M, Nattrass M. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabet Med. 1992 Jun;9(5):463-8. PubMed PMID: 1611835.
11: Arauz-Pacheco C, Ramirez LC, Pruneda L, Sanborn GE, Rosenstock J, Raskin P. The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy. J Diabetes Complications. 1992 Apr-Jun;6(2):131-7. PubMed PMID: 1611137.
12: Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, Owens DR, Rosén I, Sönksen P. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. J Diabetes Complications. 1992 Apr-Jun;6(2):123-30. PubMed PMID: 1611136.
13: Beyer-Mears A, Murray FT, Cruz E, Rountree J, Sciadini M. Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat. Pharmacology. 1992;45(5):285-91. PubMed PMID: 1465475.
14: Williams M, Mayhew TM. Responses of enterocyte microvilli in experimental diabetes to insulin and an aldose reductase inhibitor (ponalrestat). Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;62(6):385-9. PubMed PMID: 1360726.
15: Ziegler D, Mayer P, Rathmann W, Gries FA. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract. 1991 Oct;14(1):63-73. PubMed PMID: 1748064.
16: Moulds RF, Fullinfaw RO, Bury RW, Plehwe WE, Jacka N, McGrath KM, Martin FI. Ponalrestat does not cause a protein binding interaction with warfarin in diabetic patients. Br J Clin Pharmacol. 1991 Jun;31(6):715-8. PubMed PMID: 1907841; PubMed Central PMCID: PMC1368588.
17: Ramirez LC, Arauz C, Pruneda L, Hammon K, Rosenstock J, Raskin P. The effect of aldose reductase inhibition with ponalrestat on the width of the capillary basement membrane in diabetes mellitus. Diabetes Res Clin Pract. 1991 Feb;11(2):73-80. PubMed PMID: 1902410.
18: Austin CE, Chess-Williams R. Diabetes-induced changes in cardiac beta-adrenoceptor responsiveness: effects of aldose reductase inhibition with ponalrestat. Br J Pharmacol. 1991 Feb;102(2):478-82. PubMed PMID: 1849772; PubMed Central PMCID: PMC1918039.
19: Florkowski CM, Rowe BR, Nightingale S, Harvey TC, Barnett AH. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes. 1991 Jan;40(1):129-33. PubMed PMID: 1901808.
20: Pekiner C, McLean WG. Impaired induction of nerve ornithine decarboxylase activity in the streptozotocin-diabetic rat is prevented by the aldose reductase inhibitor ponalrestat. Br J Pharmacol. 1990 Dec;101(4):978-80. PubMed PMID: 2128196; PubMed Central PMCID: PMC1917828.
